Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Hybrid PET/MRI may improve detection of seizure-onset zone (SOZ) in drug-resistant epilepsy (DRE), however, concerns over PET bias from MRI-based attenuation correction (MRAC) have limited clinical adoption of PET/MRI. This study evaluated the diagnostic equivalency and potential clinical value of PET/MRI against PET/CT in DRE.
Materials And Methods: MRI, FDG-PET and CT images (n = 18) were acquired using a hybrid PET/MRI and a CT scanner. To assess diagnostic equivalency, PET was reconstructed using MRAC (RESOLUTE) and CT-based attenuation correction (CTAC) to generate PET/MRI and PET/CT images, respectively. PET/MRI and PET/CT images were compared qualitatively through visual assessment and quantitatively through regional standardized uptake value (SUV) and z-score assessment. Diagnostic accuracy and sensitivity of PET/MRI and PET/CT for SOZ detection were calculated through comparison to reference standards (clinical hypothesis and histopathology, respectively).
Results: Inter-reader agreement in visual assessment of PET/MRI and PET/CT images was 78 % and 81 %, respectively. PET/MRI and PET/CT were strongly correlated in mean SUV (r = 0.99, p < 0.001) and z-scores (r = 0.92, p < 0.001) across all brain regions. MRAC SUV bias was <5% in most brain regions except the inferior temporal gyrus, temporal pole, and cerebellum. Diagnostic accuracy and sensitivity were similar between PET/MRI and PET/CT (87 % vs. 85 % and 83 % vs. 83 %, respectively).
Conclusion: We demonstrate here that PET/MRI with optimal MRAC can yield similar diagnostic performance as PET/CT. Nevertheless, further exploration of the potential added value of PET/MRI is necessary before clinical adoption of PET/MRI for epilepsy imaging.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eplepsyres.2021.106583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.
Nuklearmedizin
September 2025
Nuclear Medicine, Ulm University Hospital, Ulm, Germany.
Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.
View Article and Find Full Text PDFCharacterization of Sinonasal Lesions on CT, MRI, and PET/CT.
Clin Nucl Med
September 2025
Department of Radiology, Division of Neuroradiology, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, FL.
The differential diagnosis of sinonasal lesions includes benign and malignant disease. Current radiologic diagnosis depends on the complementary roles of CT and MRI. PET/CT has been widely utilized for diagnosis and staging of various types of tumors as well as assessing treatment response.
View Article and Find Full Text PDFPET/CT and Paraneoplastic Syndromes: A Comprehensive Review.
Cancers (Basel)
August 2025
Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
Paraneoplastic syndromes (PNSs) are pathologic conditions produced by neoplasms not attributable to tumor invasion or metastasis. The clinical manifestations of PNSs can precede the diagnosis; these symptoms may serve as early indicators of underlying malignancy. Standard imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), have limited sensitivity in detecting small or early-stage PNS-associated tumors.
View Article and Find Full Text PDFMolecular Imaging in Endometrial Cancer: A Narrative Review.
Cancers (Basel)
August 2025
Department of Nuclear Medicine, University Hospital of Guadalajara, 19002 Guadalajara, Spain.
: Endometrial cancer (EC) is the most common gynecological tumor in developed countries, and presents a wide variety of histological and molecular characteristics that make its treatment increasingly complex. In recent years, advances in molecular imaging, particularly with [F]FDG-PET/CT and PET/MRI, have changed clinicians' management of diagnosis, treatment planning, and prognosis of EC. : In this narrative review, a search was conducted for current evidence on the role of [F]FDG-PET/CT and PET/MRI throughout the treatment of EC, focusing on their diagnostic performance, clinical relevance, and prognostic implications.
View Article and Find Full Text PDFEffect of previous Lu-DOTATATE treatment on Y-microsphere treatment response in neuroendocrine tumor patients with liver metastasis.
Ann Nucl Med
August 2025
Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Fatih, Istanbul, Turkey.
Objective: This study evaluates the impact of prior PRRT with Lu-177 DOTATATE on the response to TARE in NET patients with liver metastases.
Methods: Twenty-one patients who underwent TARE after PRRT between 2015 and 2022 were retrospectively analyzed. Tumor-specific cumulative Lu-177 DOTATATE counts were calculated from SPECT/CT images.